Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

492 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-23

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In view of the current status of prevention and research on GBS disease in mothers and infants at home and abroad, this project intends to explore the characteristics of vaginal microbiota of GBS-colonized pregnant women in southern China, the impact of IAP prevention of GBS-EOD on vaginal flora, and the effect of IAP prevention of GBS-EOD on intestinal flora and immune production in offspring, so as to improve the ability to prevent and treat GBS-related diseases in mothers and infants and promote maternal and infant health.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of IAP-EOGBSD on Offspring's Gut Microbiome and Immunity.

NCT05738460

Healthy Metabolism Microbiome

UNKNOWN

Antibiotic Exposure During Pregnancy Affects Infant Gut Microbiota

NCT06479941

Antibiotics Affecting Newborn Gut Microbiota

RECRUITING

Group B Streptococcus Infection and PROM Incidince

NCT06735703

Premature Rupture of Fetal Membranes Group B Streptococcal Infection

NOT_YET_RECRUITING

Burden of Invasive Group B Streptococcal Disease in Infants and Resistance Surveillance in China

NCT02812576

Invasive Group B Streptococcal Disease

UNKNOWN

Development and Optimization of a GBS Diagnostic Test

NCT00322829

Streptococcus Group B

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project intends to explore the characteristics of vaginal microbiota of GBS-colonized pregnant women in southern China, the impact of IAP prevention of GBS-EOD on vaginal flora, and the effect of IAP prevention of GBS-EOD on intestinal flora and immune production in offspring, so as to improve the ability to prevent and treat GBS-related diseases in mothers and infants and promote maternal and infant health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microbiome, Human

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pregnant women colonized by Group B Streptococcus (GBS) and undergoing IAP

vaginal microbiome of pregnant women colonized by Group B Streptococcus (GBS)、Pregnant women undergoing IAP

antibiotic

Intervention Type DRUG

For pregnant women with GBS colonization, antibiotics are used to prevent infection

pregnant women does not colonized by Group B Streptococcus (GBS) and not undergoing IAP

Group B streptococcus (GBS) does not colonize the vaginal microbiome of pregnant women、Pregnant wome

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

antibiotic

For pregnant women with GBS colonization, antibiotics are used to prevent infection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women are 18 to 40 years;
* 35 to 41 weeks of pregnancy;
* Singleton pregnancy;
* Plan for vaginal delivery and postpartum care in the research hospital;
* Pregnant women who volunteered to participate in the study.

Exclusion Criteria

* Have infectious diseases, serious infections and clinical diseases;
* Use of antibiotics in the past 2 weeks;
* Long-term use of drugs due to digestion, immunity, blood, chronic diseases;
* Sexual behavior, vaginal douching and topical medication within 24 hours before sampling;
* Any medical or non-medical condition that the investigator considers inappropriate to participate.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes